LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

LLY

1,103

-2.23%↓

JNJ

225.18

-2.6%↓

ABBV

217.96

-0.27%↓

UNH

378.65

-0.98%↓

MRK

118.6

-1.13%↓

Home・Elenco Azioni・AnaptysBio Inc

AnaptysBio Inc

Chiusa

SettoreSettore sanitario

55.57 -2.25

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

54.82

Massimo

55.76

Metriche Chiave
By Trading Economics
Entrata	-102M -53M
Vendite	-83M 26M
EPS	-1.843
Margine di Profitto	-206.934
Dipendenti	104
EBITDA	-102M -34M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+44.6% upside

Dividendi
By Dow Jones
Utili prossimi	4 ago 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	-272M 1.7B
Apertura precedente	57.82
Chiusura precedente	55.57

Notizie sul Sentiment di mercato

By Acuity

100%

320 / 344 Classifica in Healthcare

AnaptysBio Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 mag 2026, 23:08 UTC

Acquisizioni, Fusioni, Takeovers

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29 mag 2026, 23:06 UTC

Acquisizioni, Fusioni, Takeovers

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29 mag 2026, 20:53 UTC

Utili

Oil Declines Lift Stocks to Fresh Records -- WSJ

29 mag 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 20:33 UTC

Discorsi di Mercato

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29 mag 2026, 20:11 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 19:47 UTC

Utili

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29 mag 2026, 19:36 UTC

Discorsi di Mercato

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

29 mag 2026, 19:34 UTC

Discorsi di Mercato

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29 mag 2026, 19:22 UTC

Discorsi di Mercato

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29 mag 2026, 19:05 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29 mag 2026, 18:19 UTC

Discorsi di Mercato

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29 mag 2026, 18:12 UTC

Acquisizioni, Fusioni, Takeovers

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29 mag 2026, 18:11 UTC

Discorsi di Mercato

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29 mag 2026, 18:10 UTC

Discorsi di Mercato

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29 mag 2026, 17:55 UTC

Utili

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29 mag 2026, 17:55 UTC

Discorsi di Mercato

NEAR Protocol Nearly Doubles in May -- Market Talk

29 mag 2026, 17:38 UTC

Discorsi di Mercato

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29 mag 2026, 17:00 UTC

Utili

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Financial Services Roundup: Market Talk

29 mag 2026, 16:20 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

29 mag 2026, 16:15 UTC

Discorsi di Mercato

Global Commodities Roundup: Market Talk

29 mag 2026, 16:02 UTC

Discorsi di Mercato

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

29 mag 2026, 15:55 UTC

Discorsi di Mercato

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29 mag 2026, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29 mag 2026, 15:50 UTC

Acquisizioni, Fusioni, Takeovers

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29 mag 2026, 15:40 UTC

Discorsi di Mercato

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29 mag 2026, 15:20 UTC

Discorsi di Mercato

Canada's Economy Not Looking All That Bright -- Market Talk

Confronto tra pari

Modifica del prezzo

AnaptysBio Inc Previsione

Obiettivo di Prezzo

By TipRanks

44.6% in crescita

Previsioni per 12 mesi

Media 80.5 USD 44.6%

Alto 140 USD

Basso 50 USD

Basato su 11 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per AnaptysBio Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

11 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 11 che hanno fornito valutazioni azionarie a AnaptysBio Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

320 / 344 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.